insights_auto
Prečo akcie ADAPY klesli 3,79%?
Preskúmať podrobnejšiechevron_right
ADAPY:OTCMKTS
Adaptimmune Therapeutics PLC - ADR
0,028 USD
arrow_downward
-3,79%(-0,0011) 1 d.
7. 10., 16:00:00 GMT-4 · USD
search
Všetky symboly
| Symbol | Cena | Zmena | % zmeny |
|---|
insights_autoGenerujú sa najdôležitejšie štatistiky pre ADAPY…
Otvoriť
0,02 USD
Vysoká
0,03 USD
Nízka
0,02 USD
Trh. kap.
7,15 mil.
Priem. obj.
211,23 tis.
Objem
0,00
Max. za 52 týž.
0,28 USD
Min. za 52 týž.
0,00 USD
Beta
0,75
Akcie v obehu
265,05 mil.
Počet zamestnancov
272
Otvoriť
0,02 USD
Vysoká
0,03 USD
Nízka
0,02 USD
Trh. kap.
7,15 mil.
Priem. obj.
211,23 tis.
Objem
0,00
Max. za 52 týž.
0,28 USD
Min. za 52 týž.
0,00 USD
Beta
0,75
Akcie v obehu
265,05 mil.
Počet zamestnancov
272
Spravodajstvo
Z internetových zdrojov a od spravodajských partnerov
PR Newswire UK
·
pred 10 minútami
Skydance Debuts on NYSE Following 'Historic' Media Merger: NYSE Content Update
The Manila Times
·
pred 15 minútami
Primech Holdings (Nasdaq: PMEC) Subsidiary Earns 2026 LowCarbonSG Gold Leader Recognition Following 17.5% Year-on-Year Reduction in Scope 1 and 2 Emissions
Yahoo Finance
·
pred 41 minútami
1 S&P 500 Stock to Consider Right Now and 2 That Underwhelm
Seeking Alpha
·
pred 50 minútami
TQQQ: The Case For Going All-In Ahead Of Q3 Earnings Season (NASDAQ:TQQQ)
Profil
Adaptimmune is a biopharmaceutical company that develops T cell therapies against cancer. The company was founded in 2008 in the UK with links to both Oxford University and the University of Pennsylvania. It has headquarters in Philadelphia and Milton Park.
In August 2024, the US Food and Drug Administration granted accelerated approval to Adaptimmune's Tecelra, a therapy against a rare form of cancer. Tecelra is the first T cell therapy to be approved for use against a solid tumor. In January 2025, the FDA granted breakthrough therapy designation to Adaptimmune's Letetresgene Autoleucel for Treatment of Myxoid/Round Cell Liposarcoma.
In July 2025, Adaptimmune announced their entry into a Definitive Agreement for Sale of Tecelra, lete-cel, and the pre-clinical uza-cel to US WorldMeds for $55M. Wikipedia
Informácie o subjekte Adaptimmune Therapeutics PLC - ADR
Generálny riaditeľAdrian Rawcliffe
Zamestnanci272
Dátum založenia2008
Hlavné sídlo-
Odvetvie-